Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
C | 0.700 | CausalMutation | CLINVAR | Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. | 26619011 | 2016 |
|||
|
A | 0.700 | GeneticVariation | CLINVAR | Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. | 26619011 | 2016 |
|||
|
G | 0.700 | GeneticVariation | CLINVAR | Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. | 26619011 | 2016 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Development of molecular biomarkers in individualized treatment of colorectal cancer. | 21729679 | 2011 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. | 21305640 | 2011 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. | 21829508 | 2011 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | NRAS mutations are rare in colorectal cancer. | 20736745 | 2010 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. | 20619739 | 2010 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. | 17699718 | 2007 |
|||
|
C | 0.700 | CausalMutation | CLINVAR | BRAF mutation predicts sensitivity to MEK inhibition. | 16273091 | 2006 |